Personalis/PSNL

$1.33

1.92%
-
1D1W1MYTD1YMAX

About Personalis

Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.

Ticker

PSNL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Christopher Hall

Employees

223

Headquarters

Fremont, United States

Personalis Metrics

BasicAdvanced
$67M
Market cap
-
P/E ratio
-$1.89
EPS
1.86
Beta
-
Dividend rate
$67M
1.86271
$2.60
$0.89
288K
3.839
3.559
0.766
2.137
-39.62%
-58.92%
-46.08%
0.904
0.549
0.555
7.96%
23.25%
-2.24%

What the Analysts think about Personalis

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
245.86% upside
High $7.50
Low $3.50
$1.33
Current price
$4.60
Average price target

Personalis Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-66.15% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$20M
-0.51%
Net income
-$13M
-51.32%
Profit margin
-66.15%
-51.07%

Personalis Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 36.07%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.50
-$0.60
-$0.54
-$0.26
-
Expected
-$0.53
-$0.53
-$0.50
-$0.41
-$0.37
Surprise
-5.87%
14.03%
8%
-36.07%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Personalis stock?

Personalis (PSNL) has a market cap of $67M as of May 30, 2024.

What is the P/E ratio for Personalis stock?

The price to earnings (P/E) ratio for Personalis (PSNL) stock is 0 as of May 30, 2024.

Does Personalis stock pay dividends?

No, Personalis (PSNL) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Personalis dividend payment date?

Personalis (PSNL) stock does not pay dividends to its shareholders.

What is the beta indicator for Personalis?

Personalis (PSNL) has a beta rating of 1.86. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Personalis stock price target?

The target price for Personalis (PSNL) stock is $4.6, which is 245.86% above the current price of $1.33. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Personalis stock

Buy or sell Personalis stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing